+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometriosis Drugs Market by Drug Class, Distribution Channel, Product Type, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030- Product Image
Endometriosis Drugs Market by Drug Class, Distribution Channel, Product Type, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030- Product Image
Sale

Endometriosis Drugs Market by Drug Class, Distribution Channel, Product Type, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015277
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Endometriosis Drugs Market grew from USD 2.69 billion in 2024 to USD 2.89 billion in 2025. It is expected to continue growing at a CAGR of 7.29%, reaching USD 4.11 billion by 2030.

Understanding the Critical Landscape of Endometriosis Therapeutics

Endometriosis represents one of the most complex gynecological disorders affecting millions of women worldwide. Characterized by the growth of endometrial-like tissue outside the uterus, this condition often leads to chronic pelvic pain, infertility, and considerable setbacks in quality of life. Despite advances in surgical techniques and symptomatic therapies, the demand for safe, effective, and well-tolerated pharmaceutical treatments remains high. By understanding the evolving clinical needs and patient journeys, stakeholders can pinpoint opportunities to enhance therapeutic outcomes and alleviate the socioeconomic burdens associated with delayed diagnosis and suboptimal disease management.

The market for endometriosis drugs has matured into a sophisticated ecosystem where established therapies compete alongside novel investigational agents. Healthcare providers, payers, and patient advocacy groups are all driving a shift toward value-based care, emphasizing sustained relief, minimal adverse effects, and improved patient adherence. In this context, strategic insights into emerging drug classes, shifting reimbursement models, and patient-centric delivery platforms become essential for pharmaceutical companies seeking to navigate an increasingly competitive landscape. This executive summary offers a concise yet comprehensive foundation for informed decision-making as the market approaches its next phase of transformation.

Emerging Dynamics Redefining the Endometriosis Drugs Arena

The endometriosis drugs market is undergoing a period of unprecedented transformation as scientific breakthroughs intersect with evolving patient expectations. Revolutionary advances in precision medicine now enable the identification of molecular targets that promise more effective interventions with fewer off-target effects. At the same time, the rise of biosimilar versions of proven therapies is reshaping pricing dynamics, compelling originator companies to accelerate innovation and optimize their portfolios.

Regulatory bodies have responded to the growing public health priorities by streamlining approval pathways for therapies addressing unmet needs. Enhanced collaboration between industry and regulators has delivered expedited clinical trial designs and adaptive licensing frameworks. Digital health technologies combine with telemedicine solutions to extend care pathways beyond traditional clinical settings, fostering real-time monitoring of symptom progression and treatment compliance. Collectively, these shifts are redefining how drugs are discovered, approved, and delivered, offering new growth vectors for agile market participants.

Assessing the Impact of U.S. Tariffs on Drug Supply and Pricing

In 2025, significant adjustments to United States import tariffs have introduced new complexities into pharmaceutical supply chains. These measures, implemented to bolster domestic manufacturing and protect critical industries, have led to variable cost increases for active pharmaceutical ingredients sourced internationally. Manufacturers are now recalibrating sourcing strategies and negotiating with suppliers to mitigate the financial impact of elevated tariff rates. This evolution in trade policy underscores the need for robust supply chain risk management and diversified procurement approaches.

The ripple effects of tariff-induced cost pressures extend to pricing negotiations with payers and healthcare providers. Firms are exploring alternative raw material suppliers, including domestic producers, while engaging in value-based contracting to secure formulary access. Some companies are accelerating investments in local manufacturing facilities to ensure supply continuity and reduce exposure to cross-border cost fluctuations. As a consequence, operational agility and strategic foresight have become essential competencies for industry leaders striving to uphold competitive positioning in a shifting tariff environment.

Unveiling Deep Market Segmentation Patterns for Strategic Clarity

Rigorous analysis across multiple segmentation dimensions reveals nuanced trends that can guide tailored strategies. When the market is examined by drug class, aromatase inhibitors consistently demonstrate efficacy in reducing estrogen levels, while gonadotropin-releasing hormone analogs, both long-acting and short-acting, maintain strong adoption due to their sustained symptom relief. Non-steroidal anti-inflammatory drugs continue to serve as frontline pain management options, whereas oral contraceptives-spanning biphasic, monophasic, and triphasic formulations-offer versatile hormonal regulation. Progestins remain indispensable for patients seeking low-risk maintenance therapy, highlighting the importance of class-specific positioning and physician education.

A detailed exploration of distribution channels highlights how hospital pharmacies, including both private and public institutions, facilitate broad access to advanced therapies. Simultaneously, direct-to-consumer online pharmacies and platform-based e-commerce models are emerging as convenient conduits for patient support programs. Chain retail outlets and independent drugstores uphold patient loyalty through community engagement and personalized counseling. Firms that adapt channel strategies to local infrastructure and patient preferences gain a clear advantage in reaching diverse target segments.

When evaluating product type, branded formulations capitalize on proprietary delivery technologies and robust clinical trial data, while generic counterparts rapidly expand treatment affordability and penetration. Injectable routes of administration enjoy preference among patients requiring infrequent dosing and consistent therapeutic levels, even as oral regimens remain dominant for day-to-day management. Topical applications, though currently limited, are gaining attention as developers seek non-invasive alternatives with localized efficacy.

End users such as specialized clinics spearhead early diagnosis and tailored treatment initiation, while home healthcare services foster compliance through telemonitoring and nurse-led interventions. Hospitals continue to manage acute exacerbations and surgical interventions, underscoring the complementary roles of each setting. Finally, therapies characterized by hormonal modulation underpin the foundational approach to disease control, whereas targeted pain management agents deliver vital symptomatic relief, suggesting that combination regimens will drive future innovation.

Regional Variations Offering Pathways to Growth Optimization

The Americas lead with a mature regulatory environment and well-established reimbursement frameworks, encouraging rapid adoption of innovative therapies. North American healthcare systems are embracing personalized medicine, while Latin American markets show potential for generics-driven expansion supported by public health initiatives. Meanwhile, Europe, Middle East and Africa present a spectrum of access realities: Western Europe benefits from centralized approvals and comprehensive formulary coverage, whereas parts of the Middle East and Africa face challenges related to healthcare infrastructure and variable pricing regulations. Stakeholders in these regions navigate complex policy landscapes to ensure equitable treatment availability.

Asia-Pacific stands out as a high-growth frontier. Rising awareness of endometriosis, coupled with expanding healthcare budgets in key markets, is fueling demand for both branded and generic drugs. Regulatory harmonization efforts are streamlining clinical trials and market entry, while local manufacturing hubs are reducing costs and fostering supply reliability. Governments are investing in patient education campaigns, which in turn drive earlier diagnosis and improved treatment adherence. Market participants that align commercial strategies with regional healthcare priorities will find untapped opportunities across this dynamic region.

Competitive Intelligence on Leading Endometriosis Treatment Innovators

A competitive landscape analysis highlights how leading pharmaceutical companies are strategically positioning their portfolios for sustained growth. Major players are accelerating research collaborations to enrich their pipelines with next-generation hormonal and non-hormonal agents. Several firms have entered licensing agreements with biotech innovators to gain early access to promising candidates in Phase II and Phase III trials. In parallel, established drugmakers are investing in manufacturing capacity expansions and global distribution networks to secure supply continuity and expand their geographic reach.

Emerging organizations specializing in biosimilars are disrupting traditional pricing models, driving down costs and enhancing treatment accessibility. Venture-backed start-ups are leveraging novel drug delivery technologies, such as sustained-release implants and transdermal systems, to differentiate their offerings. Strategic acquisitions have become a core tactic for large companies seeking to bolster their late-stage pipelines, while partnerships with digital health ventures are enabling integrated patient support services. This confluence of collaboration, innovation, and strategic M&A underscores the dynamic competitive interplay defining the endometriosis drugs market.

Strategic Actions to Lead in the Evolving Therapeutics Market

Industry leaders should prioritize the development of long-acting and patient-tailored formulations to address unmet clinical needs and enhance adherence. Integrating real-world evidence into clinical trial designs and post-market studies will strengthen payer negotiations and support premium positioning. Optimizing distribution networks by forging alliances with both public and private hospital pharmacies, as well as expanding direct-to-consumer online platforms, can accelerate market penetration and improve patient access.

Cost-containment pressures demand a proactive approach to generics and biosimilar development. Companies can leverage existing manufacturing expertise to enter this segment, thereby capitalizing on the anticipated shift toward lower-priced alternatives. Geographic diversification into high-potential Asia-Pacific and Latin American markets requires culturally adapted marketing strategies and local stakeholder engagement. Lastly, enhancing patient support through digital health tools and nurse-led programs will cultivate brand loyalty, improve treatment outcomes, and differentiate offerings in an increasingly crowded landscape.

Robust Methodology Ensuring Reliable Market Insights

This research employs a mixed-methodology approach, combining in-depth interviews with leading clinicians, regulatory experts, and industry executives to capture primary insights. Secondary data was sourced from peer-reviewed journals, regulatory databases, corporate filings, and global market intelligence platforms. Each data point underwent rigorous validation protocols, including cross-referencing with public health statistics and industry association reports.

Quantitative findings were subjected to statistical scrutiny to identify growth drivers, market share dynamics, and pricing trends. Qualitative inputs enriched the analysis with contextual understanding of patient journeys, treatment pathways, and stakeholder priorities. A systematic triangulation process ensured consistency across diverse data sources, while internal quality audits and expert peer reviews upheld methodological transparency and reliability. This robust framework underpins the credibility of the insights presented throughout this executive summary.

Driving Future Directions in Endometriosis Drug Development

The endometriosis drugs market stands at a pivotal juncture, shaped by scientific breakthroughs, evolving regulatory frameworks, and shifting patient expectations. Key insights reveal that targeted hormonal therapies and advanced delivery mechanisms will fuel the next wave of innovation, while pricing pressures and tariff impacts require agile supply chain and commercialization strategies. Regional disparities underscore the need for tailored market entry plans, and segmentation analysis highlights the importance of channel optimization and patient-centric offerings.

As companies navigate this complex environment, a strategic balance between branded portfolio expansion and cost-effective generics or biosimilars will be essential. Collaborative partnerships, digital health integration, and robust real-world evidence generation will further differentiate market leaders. By embracing these insights and recommendations, stakeholders can effectively respond to unmet clinical needs, improve patient outcomes, and secure sustainable growth in a competitive arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Aromatase Inhibitors
    • GnRH Analogs
      • Long-Acting
      • Short-Acting
    • NSAIDs
    • Oral Contraceptives
      • Biphasic
      • Monophasic
      • Triphasic
    • Progestins
  • Distribution Channel
    • Hospital Pharmacies
      • Private Hospital Pharmacies
      • Public Hospital Pharmacies
    • Online Pharmacies
      • Direct-To-Consumer Online Pharmacies
      • Platform-Based Online Pharmacies
    • Retail Pharmacies
      • Chain Retail Pharmacies
      • Independent Retail Pharmacies
  • Product Type
    • Branded
    • Generic
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
  • Mechanism Of Action
    • Hormonal Therapy
    • Pain Management
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Bayer AG
  • Ferring Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy’s Laboratories Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Endometriosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Aromatase Inhibitors
8.3. GnRH Analogs
8.3.1. Long-Acting
8.3.2. Short-Acting
8.4. NSAIDs
8.5. Oral Contraceptives
8.5.1. Biphasic
8.5.2. Monophasic
8.5.3. Triphasic
8.6. Progestins

9. Endometriosis Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Private Hospital Pharmacies
9.2.2. Public Hospital Pharmacies
9.3. Online Pharmacies
9.3.1. Direct-To-Consumer Online Pharmacies
9.3.2. Platform-Based Online Pharmacies
9.4. Retail Pharmacies
9.4.1. Chain Retail Pharmacies
9.4.2. Independent Retail Pharmacies

10. Endometriosis Drugs Market, by Product Type
10.1. Introduction
10.2. Branded
10.3. Generic

11. Endometriosis Drugs Market, by Route of Administration
11.1. Introduction
11.2. Injectable
11.3. Oral
11.4. Topical

12. Endometriosis Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Healthcare
12.4. Hospitals

13. Endometriosis Drugs Market, by Mechanism of Action
13.1. Introduction
13.2. Hormonal Therapy
13.3. Pain Management

14. Americas Endometriosis Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina

15. Europe, Middle East & Africa Endometriosis Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland

16. Asia-Pacific Endometriosis Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan

17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Myovant Sciences GmbH
17.3.3. Pfizer Inc.
17.3.4. Bayer AG
17.3.5. Ferring Pharmaceuticals Inc.
17.3.6. Teva Pharmaceutical Industries Ltd.
17.3.7. Sandoz International GmbH
17.3.8. Viatris Inc.
17.3.9. Sun Pharmaceutical Industries Limited
17.3.10. Dr. Reddy’s Laboratories Limited

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

List of Figures
FIGURE 1. ENDOMETRIOSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ENDOMETRIOSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ENDOMETRIOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables
TABLE 1. ENDOMETRIOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DIRECT-TO-CONSUMER ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PLATFORM-BASED ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 73. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 75. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 76. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 77. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 172. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 173. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 176. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 247. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 249. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 250. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 252. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 253. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 254. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 299. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 324. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 327. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 329. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 330. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 331. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Endometriosis Drugs market report include:
  • AbbVie Inc.
  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Bayer AG
  • Ferring Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy’s Laboratories Limited

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.11 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Endometriosis Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Endometriosis Treatment Market by Treatment Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Endometriosis Treatment Market by Treatment Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Endometriosis Treatment Market Report and Forecast 2024-2032 - Product Image

Endometriosis Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Endometriosis Market Report 2025 - Product Image

Endometriosis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Endometriosis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Endometriosis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From

About the Endometriosis Drug Market

The Endometriosis Drug market is a subset of the Immune Disorders Drugs market. Endometriosis is a condition in which the tissue that normally lines the uterus grows outside of the uterus, causing pain and other symptoms. Endometriosis drugs are used to treat the symptoms of endometriosis, such as pain, heavy menstrual bleeding, and infertility. These drugs can be divided into two categories: hormonal therapies and non-hormonal therapies. Hormonal therapies include oral contraceptives, progestins, and gonadotropin-releasing hormone agonists. Non-hormonal therapies include non-steroidal anti-inflammatory drugs, danazol, and GnRH antagonists. Some companies in the Endometriosis Drug market include AbbVie, Allergan, Bayer, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.